Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- CT scans showing mixed or solid lung spots that have been confirmed by laboratory tissue or cell testing as non-small cell lung cancer (NSCLC), at an early to mid stage (tumour 5 cm or smaller, not spread to nearby lymph nodes or other parts of the body), based on standard cancer staging guidelines.
- The cancer has a specific gene change (mutation) in a protein called EGFR — either a deletion in exon 19 or a specific change in exon 21 called L858R.
- People aged 18 or older.
- People who are reasonably active and able to carry out daily activities, as measured by a standard health scoring tool (a score of 0–2 on the ECOG scale).
- People with an expected survival of at least 3 months.
- People for whom a specialist team has decided that surgery or radiotherapy is not suitable, or who have chosen not to have surgery or radiotherapy.
- People who have not previously received any EGFR-targeted drug therapy.
- People who are willing to have the initial ablation procedure, are able to attend follow-up appointments reliably, and are able to understand and sign a consent form for the study.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People with serious problems affecting the liver, kidneys, heart, lungs, or brain, or other health conditions that could make it unsafe to undergo the treatment procedures used in this trial.
- People whose chest CT scan shows that the lung tumour cannot safely be reached through the skin for the ablation procedure.
- People with a very low platelet count (below 50×10⁹/L), a serious tendency to bleed, or blood clotting problems that cannot be corrected.
- People who are currently using or have used anti-cancer drugs or EGFR-targeted therapy within the past 3 months.
- People with health conditions that are not well controlled, including (but not limited to) other cancers outside the lungs, active infections, severe heart failure, unstable chest pain, irregular heart rhythms, or psychiatric disorders.
- Women who are pregnant, breastfeeding, or planning to become pregnant during the study period.
- People who the trial investigators consider unsuitable for the study for any other reason (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jiayuan Sun, MD, PHD, Shanghai Chest Hospital
Phone: +13262251689
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
3-year disease-free survival (DFS) rate in the MWA-TKI and TKI-MWA-TKI groups
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.